Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Denovo Biopharma LLC clinical trials
The registry lists 22 studies whose lead sponsor is Denovo Biopharma LLC. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 15, 2026.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Denovo Biopharma LLC.
- Denovo Biopharma LLC22 studiesSame company
Something wrong?
Focus areas
Conditions Denovo Biopharma LLC leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 22 of 22.
- The Effects of Urinary pH Changes on an Investigational Compound in Healthy SubjectsCompletedNCT01440478Phase 1
- A Long-Term, Open-Label, Study on SchizophreniaTerminatedNCT01129674Phase 2/3
- A Comparator Study of LY2140023 Versus Placebo in Schizophrenia PatientsCompletedNCT01086748Phase 2
- A Study for Participants With SchizophreniaCompletedNCT00520923Phase 2
- A Long-Term Safety Study of Pomaglumetad Methionil in SchizophreniaTerminatedNCT01487083Phase 3
- A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRDCompletedNCT05113771Phase 2
- Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™CompletedNCT03263026Phase 3
- A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1CompletedNCT03776071Phase 3
- A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With SchizophreniaCompletedNCT01606436Phase 1
- A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic PatientsCompletedNCT00845026Phase 2
- A Study of LY2140023 in Patients With SchizophreniaTerminatedNCT01307800Phase 3
- A Physical Dependence Study in SchizophreniaCompletedNCT01452919Phase 3
- A Study of Safety and Tolerability in Subjects With SchizophreniaCompletedNCT01354353Phase 1
- A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia PatientsTerminatedNCT01328093Phase 3
- A Study of LY2140023 in Schizophrenia Patients With Prominent Negative SymptomsCompletedNCT01052103Phase 2
- A Study of LY2140023 in Hepatically-Impaired ParticipantsCompletedNCT01475136Phase 1
- A Study of LY2140023 in Healthy Males and FemalesCompletedNCT01591330Phase 1
- A Study of LY2140023 in Healthy ParticipantsCompletedNCT01609218Phase 1
- A Study of LY2140023 in Healthy ParticipantsCompletedNCT01637142Phase 1
- A Study in Schizophrenic PatientsTerminatedNCT01125358Phase 2
- A Study of LY2140023 in Healthy ParticipantsWithdrawnNCT01659177Phase 1
- Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and PlaceboCompletedNCT00149292Phase 2